登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 84010 条符合本次的查询结果， 用时 2.0507524 秒

1841. Chemotherapy-Related Chronic Nerve Pain More Common Than Expected.

作者: Samantha Anderer.
来源: JAMA. 2025年

1842. FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression.

作者: Samantha Anderer.
来源: JAMA. 2025年

1843. Metabolic Surgery May Lessen Liver Disease Complications, Lower Costs.

作者: Samantha Anderer.
来源: JAMA. 2025年

1844. Fresh Embryos May Boost IVF Outcomes for Women With Low Likelihood of Success.

作者: Samantha Anderer.
来源: JAMA. 2025年

1845. Deleting My Mother's Email Account.

作者: David Rosenblum.
来源: JAMA. 2025年

1846. Excerpt From Hospice Care Daily.

作者: Lisa Grove.
来源: JAMA. 2025年

1847. Incidentally Detected Ascending Thoracic Aortic Aneurysm and Bicuspid Aortic Valve.

作者: Merlin G Butler.
来源: JAMA. 2025年

1848. What Is Calcific Aortic Stenosis?

作者: Jessica P Ammon.;Xavier Prida.;Christopher D Jackson.
来源: JAMA. 2025年

1849. Incidentally Detected Ascending Thoracic Aortic Aneurysm and Bicuspid Aortic Valve-Reply.

作者: Nicholas Oh.;Eric E Roselli.;Patrick R Vargo.
来源: JAMA. 2025年

1850. Prevalence and Control of Diabetes Among US Adults, 2013 to 2023.

作者: Kosuke Inoue.;Michael Liu.;Rahul Aggarwal.;Lucas X Marinacci.;Rishi K Wadhera.
来源: JAMA. 2025年333卷14期1255-7页

1851. Current Comment.

来源: JAMA. 2025年

1852. Medicaid Spending and Health-Related Social Needs in the North Carolina Healthy Opportunities Pilots Program.

作者: Seth A Berkowitz.;Jessica Archibald.;Zhitong Yu.;Myklynn LaPoint.;Salma Ali.;Maihan B Vu.;Gaurav Dave.;Kori B Flower.;Marisa Elena Domino.
来源: JAMA. 2025年333卷12期1041-50页
Health-related social needs are drivers of worse health and high health care spending. In North Carolina Medicaid's 1115 waiver, the Healthy Opportunities Pilots (HOP) program allows for nonmedical services to address health-related social needs, such as healthy food boxes and housing navigation, financed by Medicaid, in 3 regions of North Carolina.

1853. A 25-Year-Old With Verrucous Pustules and Fevers.

作者: Carlos Seas.;Paloma Rosanna Seas.;Pedro Legua.
来源: JAMA. 2025年

1854. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis.

作者: Kensuke Matsushita.;Kengo Terasaka.;Kiyoshi Hibi.
来源: JAMA. 2025年

1855. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis.

作者: Yuan-Yuan Pei.
来源: JAMA. 2025年

1856. Unintentional Fentanyl Use Detected in Hair of People With HIV Risk Using Methamphetamine.

作者: Ayesha Appa.;Matthew A Spinelli.;Marjan Javanbakht.;M J Heise.;Hideaki Okochi.;Alexander R Bazazi.;Phillip Coffin.;Pamina M Gorbach.;Monica Gandhi.
来源: JAMA. 2025年333卷14期1257-9页

1857. Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis-Reply.

作者: Neil J Craig.;David E Newby.;Marc R Dweck.
来源: JAMA. 2025年

1858. A New Legal Standard for Medical Malpractice.

作者: Daniel G Aaron.;Christopher T Robertson.;Louise P King.;William M Sage.
来源: JAMA. 2025年
Patients in the US have persistent needs for safe, evidence-based care. Physicians in the US report fear of liability risk and the need to practice "defensive medicine." In 2024, the American Law Institute revised the legal standard for assessing medical negligence. Understanding the implications of this change is crucial for balancing patient safety, physician autonomy, and the legal system's role in health care.

1859. PD-1 or PD-L1-A Difference That Makes No Difference?

作者: Samuel J Klempner.;Jeeyun Lee.;Raghav Sundar.
来源: JAMA. 2025年333卷15期1296-1298页

1860. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.

作者: Xiaotian Zhang.;Jufeng Wang.;Gang Wang.;Yanqiao Zhang.;Qingxia Fan.;Chuangxin Lu.;Changlu Hu.;Meili Sun.;Yiye Wan.;Sanyuan Sun.;Junye Wang.;Li Zhang.;Yongqian Shu.;Jie Luo.;Dan Zhu.;Zhenwei Shen.;Sheng Yao.;Qingmei Shi.;Jason Yang.;Lin Shen.; .
来源: JAMA. 2025年333卷15期1305-1314页
Gastric cancer, including gastroesophageal junction cancer, is one of the most commonly diagnosed cancers worldwide, with high mortality. Sugemalimab is a fully human anti-programmed death-ligand 1 (PD-L1) antibody. The combination of sugemalimab and chemotherapy showed promising antitumor activity and safety in a phase 1b study among patients with treatment-naive, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This combination was further evaluated in the GEMSTONE-303 phase 3 trial.
共有 84010 条符合本次的查询结果， 用时 2.0507524 秒